Appointment of Chief Technology Officer

RNS Number : 5277G
Advanced Medical Solutions Grp PLC
27 July 2021

27 July 2021

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Appointment of Chief Technology Officer


AMS strengthens its senior leadership team with appointment of industry leader Chris Locke to newly created role of Chief Technology Officer


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, is pleased to announce that on 9 August, Chris Locke will join the Group’s senior management team as Chief Technology Officer.


In this role Chris will take full responsibility for all innovation, research, development and technology assessments for the Group. He will be responsible for delivering the increasing pipeline of high value innovation projects within our expanding portfolio, as well as identifying external technology opportunities complementary to the business.


Chris joins AMS from Acelity, having spent 20 years as a senior manager within the $1.6 billion global KCI franchise, where he was instrumental in the development, creation and launch of their world-leading NPWT therapy range and other wound-care & surgical technologies. Most recently he was Acelity’s Chief Innovation Officer and prior to that held roles as Vice President, Research & Technology, Senior Director Global Innovation & Strategic Marketing, and Director, Engineering, Design & Technology. Chris is the named inventor on more than 500 US patent applications and 329 granted US patents.


Chris Meredith, Chief Executive Officer of Advanced Medical Solutions, said: “I am delighted to welcome Chris to the senior management team. He brings a wealth of experience which will help to drive further process improvement and delivery success from our growing and innovative product portfolio.”


Chris Locke, incoming Chief Technology Officer of Advanced Medical Solutions, said: “I am very pleased to be joining AMS. I look forward to contributing to the Company’s continued growth as we deliver quality outcomes for patients through innovative surgical and woundcare products.”


Ends –


For further information, please contact:


Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Matthew Cole

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Gary Clarence / Patrick Robb


About Advanced Medical Solutions Group plc 


AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.